Salinas MC, Hernández LA, Oropeza R, Olvera GC, Poblano MM, Juvenal Franco GJ

Language: Spanish
References: 17
Page: 173-177
PDF size: 185.20 Kb.

ABSTRACT

Introduction: The prevalence of infection by multidrug resistant Pseudomonas aeruginosa (MDRP) increases mortality in critically ill patients. This is why antibiotics as colistin have been developed.
Objective: To evaluate the efficacy of colistin in the treatment of MDRP. Observational retrospective study.
Results: We included 15 patients with MDRP: 54% female with mean age of 57 years, APACHE II score 18, and SOFA 11. Site of infection was the lung in first place (53%). There was clinical improvement in 80% of the patients with 53% of negative cultures (previously positive) 48 hours later. The number of days of treatment was 16.6, with renal detriment in 12% and mortality in 27%. Mean length of stay before treatment was 45 and after treatment 16.
Conclusions: Colistin was efficient as treatment for MDRP as demonstrated by clinical and bacteriologic improvement.

REFERENCES

1. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001;119:397S–404S.

2. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrugresistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111–8.

3. Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria. Crit Care Med 2001;29(4 Suppl):N75–83

4. Jean Loui Trouille, MD. Multiresistant Pseudomonas respiratory infection in Intensive Care Unit Patients. Clin Pulm Med. 2005;12 (1 ).

5. Helen Giamarellou, MD. Current Therapies for Pseudomonas aeruginosa. Crit Care Clin. 2008;24:261- 78.

6. Jian Li, Roger Nation. Colistin: the re-emerging antibiotic for multidrug-resistant Gram Negative bacterial infections. Lancet Infect Dis 2006; 6: 589- 601.

7. Hanberger H, Diekema D, Fluit A, et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001;48:161–76.

8. Dimitrios K. Matthaiou. Risk Factors associated with the isolation of colistin-resistant Gram Negative bacterias: A matched case control study. Crit Care Med 2008;36(3).

9. Hatem Kallel, Mabrouk Bauloul. Colistin as salvage for nosocomial infections cause by multidrug. Resistant bacterias in the ICU. Int J Antmicrob Agents. 2006;28:366- 9.

10. Falagas M, Kasiakou S, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138–46.

11. Falagas M, Michalopoulos A. Polymyxins: old antibiotics come back. Lancet 2006; 367:633–4.

12. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11–25.

13. Pintado V. Garcia L.et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug resistant gram-negative bacterias. J Infection 2008;56: 185-90.

14. Linden Peter. Use of parenteral colistin for the treatment of serior infection due to antimicrobial resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: e154- 60.

15. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008; 24:377-91.

16. Linden Peter. Use of parenteral colistin for the treatment of serior infection due to antimicrobial resistant Pseudomonas aeruginosa. Clin Infec Dis 2003;37:e154- 60.

17. Mentzelopoulos S, Pratikaki M, Platsouka E, et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 2007; 33:1524–32.